These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28487159)

  • 21. Optimal timing for interim analyses in clinical trials.
    Togo K; Iwasaki M
    J Biopharm Stat; 2013; 23(5):1067-80. PubMed ID: 23957516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reasons for Premature Conclusion of Late Phase Clinical Trials: An Analysis of ClinicalTrials.gov Registered Phase III Trials.
    Guinn D; Wilhelm EE; Shoulson I
    Ther Innov Regul Sci; 2020 Jan; 54(1):232-239. PubMed ID: 32008239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insufficient recruitment and premature discontinuation of clinical trials in Switzerland: qualitative study with trialists and other stakeholders.
    Briel M; Elger B; von Elm E; Satalkar P
    Swiss Med Wkly; 2017; 147():w14556. PubMed ID: 29185240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Self-designing trial combined with classical group sequential monitoring.
    Yin G; Shen Y
    J Biopharm Stat; 2005; 15(4):667-75. PubMed ID: 16022171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Should Clinical Trials Be Terminated Early?
    Streiner DL
    Clin Ther; 2019 Sep; 41(9):1889-1891. PubMed ID: 31351677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome.
    Choodari-Oskooei B; Parmar MK; Royston P; Bowden J
    Trials; 2013 Jan; 14():23. PubMed ID: 23343147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Data monitoring committees for pragmatic clinical trials.
    Ellenberg SS; Culbertson R; Gillen DL; Goodman S; Schrandt S; Zirkle M
    Clin Trials; 2015 Oct; 12(5):530-6. PubMed ID: 26374679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonpublication and discontinuation of randomised controlled trials in newborns.
    Rüegger CM; Dawson JA; Donath SM; Owen LS; Davis PG
    Acta Paediatr; 2017 Dec; 106(12):1940-1944. PubMed ID: 28871629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating the rate and reasons of clinical trial failure in urologic oncology.
    Stensland KD; DePorto K; Ryan J; Kaffenberger S; Reinstatler LS; Galsky M; Canes D; Skolarus TA; Moinzadeh A
    Urol Oncol; 2021 Mar; 39(3):154-160. PubMed ID: 33257221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring reasons for recruitment failure in clinical trials: a qualitative study with clinical trial stakeholders in Switzerland, Germany, and Canada.
    Briel M; Elger BS; McLennan S; Schandelmaier S; von Elm E; Satalkar P
    Trials; 2021 Nov; 22(1):844. PubMed ID: 34823582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance and predictors of recruitment success in National Heart, Lung, and Blood Institute's cardiovascular clinical trials.
    Pemberton VL; Evans F; Gulin J; Rosenberg E; Addou E; Burns KM; Gordon DJ; Pearson GD; Kaltman JR
    Clin Trials; 2018 Oct; 15(5):444-451. PubMed ID: 30084662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early Termination of Clinical Trials for Futility - Considerations for a Data and Safety Monitoring Board.
    Ellenberg SS; Shaw PA
    NEJM Evid; 2022 Jul; 1(7):EVIDctw2100020. PubMed ID: 38319261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early Termination of Acute Stroke Randomized Controlled Trials Published Between 2013 and 2020: A Systematic Review.
    Strong B; Oostema JA; Nikroo N; Hussain M; Reeves MJ
    Circ Cardiovasc Qual Outcomes; 2021 Dec; 14(12):e007995. PubMed ID: 34932376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prematurely ended phase III trials in Sweden during the years 2002-2008.
    Hedenmalm K; Johansson A; Bäckman K; Ohagen P
    Eur J Clin Pharmacol; 2011 Sep; 67(9):869-75. PubMed ID: 21399946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reporting on data monitoring committees in neonatal randomised controlled trials is inconsistent.
    Perrem LM; Gosling S; Ravikumar I; Khashan AS; Miletin J; Ryan CA; Dempsey E
    Acta Paediatr; 2017 Jan; 106(1):30-33. PubMed ID: 27637413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stopping clinical trials early for benefit: impact on estimation.
    Freidlin B; Korn EL
    Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternative views on setting clinical trial futility criteria.
    Gallo P; Mao L; Shih VH
    J Biopharm Stat; 2014; 24(5):976-93. PubMed ID: 24933121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.